Sarepta Therapeutics Inc (NASDAQ:SRPT)

CAPS Rating: 3 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.


Player Avatar lbsterling22 (< 20) Submitted: 1/13/2013 7:11:24 PM : Outperform Start Price: $25.94 SRPT Score: +3.46

It's not necessary for an investment to be in an ethical company, but it's a nice side-benefit. SRPT, has no significant side effects and the mainalternative for Duchenne sufferers is a heartbreaking slide into incapacity and death. This type of innovation is what modern medicine is for, and the FDA will approve it ASAP, and its developers (and investors) should and will, I believe, be richly rewarded. Dare I mention it will also make Duchenne sufferers more productive (therefore happier) members of society?

Featured Broker Partners